Loading...
Market
What will be HyperVue™ Imaging System's market share in coronary artery disease imaging by end of 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market research reports from reputable firms like Gartner or IDC
Story
SpectraWAVE Secures $50M Series B Led by Johnson & Johnson for HyperVue™ Expansion
Sep 11, 2024, 01:02 PM
SpectraWAVE has announced a $50 million Series B financing round aimed at driving commercial expansion and product additions to its HyperVue™ Imaging System. The funding round is led by Johnson & Johnson, with participation from Lumira Ventures, Deerfield Management, SV Health Investors, and S3 Ventures. CEO Eman Namati stated that this financing is expected to significantly enhance SpectraWAVE's capabilities in improving treatment and outcomes for patients with coronary artery disease.
View original story
Similar markets
Less than 10% • 33%
10% to 25% • 33%
More than 25% • 33%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31%+ • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Increase by more than 5% • 25%
Increase by 2-5% • 25%
Increase by less than 2% • 25%
No significant increase • 25%
Market share increases • 25%
Market share remains the same • 25%
Market share decreases • 25%
Foresight exits cancer-detection market • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
0-10% • 25%
11-25% • 25%
26-50% • 25%
51%+ • 25%
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
More than 40% • 25%
Google Health • 25%
IBM Watson Health • 25%
GE Healthcare • 25%
Philips Healthcare • 25%
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
More than 40% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%